GW Pharmaceuticals is known as a world leader in developing regulatory approved cannabis-based medicines. Their main focus is on plant derived therapeutics. Their development spans across many therapeutic solutions that are currently in the clinical stages.

In a previous release in Cannabexchange we highlighted the studies and benefits of Epidyolex (Cannabidiol). The therapeutic was studied on children 2 years and older. It has since been approved by the FDA and recently, the UK has de-scheduled the drug from a controlled substance schedule 2 to schedule 5 according to a recent press release.

Considering all the COVID-19 hurdles, is this stock poised to give big returns come 2021? According to Zacks Market Edge in a recent Yahoo Finance release, this stock may be a winner, now that the drug has been de-scheduled from a schedule 2 to a schedule 5 controlled substance. Is it your time to buy? Maybe having a conversation with your financial advisors could shed some light on this topic.

For the small investor, Zynerba Pharmaceuticals may seem like an opportunity waiting to happen. This company is currently trading at $6.30 since June 26th, 2020. Compared to GW Pharmaceuticals currently trading at over $120 since the same date.

Zynerba Pharmaceuticals is known as an organization that’s working towards the development of very rare form of neuropsychiatric conditions. This encompasses conditions such as Autism Spectrum Disorder, Fragile X syndrome and developmental and epileptic encephalopathies. While the company currently has no revenue and is a micro-cap biotech venture, it has nonetheless increased their shares by 3% year to date. Small invertors looking to get into the cannabis pharmaceutical game will want to keep their eye on this one.

According to Zacks Market Edge, this is one stock that’s under the Wall Street radar, for the time being. However, it was still handpicked by Zacks experts as 1 of 5 cannabis stocks that will see further increases in the near future.